Multiple synthetic inhibitors that affect Cdk5 activity (such as roscovitine, olomoleucine, and purvalanol-A) have been discovered and proven to exert neuroprotective effects in preclinical research on stroke and TBI12. The gene discussed is CDK5; the disease is stroke disorder.